AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04165785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OPT IPL
Description: Intense pulsed light (IPL) is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 IPL treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
Study NCT04165785 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham OPT IPL
Description: Sham Optimal pulsed technology intense pulsed light IPL will be implemented with an IPL device in which all light is blocked by a filter. Subjects will receive a total of 4 sham treatments over the course of the study, at intervals of 2 weeks. Each treatment will include applications of 24 sham pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression.
Study NCT04165785 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MGX
Description: Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
Study NCT04165785 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: MGX
Description: Meibomian gland expression (MGX) will be implemented by squeezing the meibomian glands with the aid of stainless steel jaeger lid plate positioned in the inferior fornix space between the tarsal and bulbar conjunctiva, and a cotton swab in another side.
Study NCT01388764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
Study NCT03116893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509 After Standardised Breakfast
Description: High-fat high calorie breakfast
Study NCT03116893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administration of itraconazole together with BI 685509
Study NCT03116893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Administration of rifampicin together with BI 685509
Study NCT03116893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 685509 Fasted Conditions
Description: BI 685509, given alone
Study NCT04561193 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT04579185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation
Description: Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
Study NCT01694030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attachment security priming
Study NCT00292266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebif®
Description: Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
Study NCT00292266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avonex®
Description: Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
Study NCT03454776 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Unloader One brace
Description: A knee brace used to unload affected compartments in osteoarthritic knees
Study NCT03454776 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo brace
Description: A knee brace that feels and looks like Unloader One but without active straps facilitating unloading of the knee
Study NCT01050712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Carbon Monoxide
Description: Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
Study NCT01050712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Synthetic Air
Description: Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
Study NCT03391180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICON Remineralization
Description: A material used for the Remineralization of white spot lesions.
Study NCT03391180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACPF
Description: Casein phosphopeptide-Amorphous calcium phosphate fluoride used for the remineralization of white spot lesions.
Study NCT01186354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Receiving results via genetic counselor
Description: participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
Study NCT00531323 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TMC125 once daily
Description: Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
Study NCT00531323 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TMC125 twice daily
Description: Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
Study NCT00735410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal Influenza Vaccine
Description: 1 dose of Split influenza vaccine
Study NCT04388202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: FDA approved antidepressant
Study NCT04388202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: FDA approved antidepressant
Study NCT03122769 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 11C-metformin
Description: 200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
Study NCT00923338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Biodesign (Vesico-vaginal fistula plug)
Description: Vesico-vaginal fistula plug
Study NCT01616667 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
Study NCT01320904 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NMES
Description: We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).~We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation.
Study NCT01320904 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Closed Kinetic Chain
Description: During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diasip
Description: Nutritional drinks for diabetics
Study NCT02278380 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Test product
Description: Test product not patented yet
Study NCT02717676 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Episiotomy
Description: episiotomy will be done after crowning of the fetal head
Study NCT01069094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenta
Description: 12.5 mg, administered as a once daily oral dose for 90 days.
Study NCT01069094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenta
Description: 25 mg, administered as a once daily oral dose for 90 days.
Study NCT02197000 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DIM-Avail 100mg
Description: DIM 100 mg\*1 daily for 2 years
Study NCT03053960 — intervention group
Intervention type: DEVICE
Intervention: Computed Tomography
Description: Undergo helical CT scan
Study NCT03053960 — intervention group
Intervention type: DEVICE
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET/CT scan
Study NCT01069094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progenta
Description: 50 mg, administered as a once daily oral dose for 90 days.
Study NCT03053960 — intervention group
Intervention type: DEVICE
Intervention: Cone-Beam Computed Tomography
Description: Undergo CBCT scan
Study NCT03053960 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan
Study NCT03053960 — intervention group
Intervention type: PROCEDURE
Intervention: Therapeutic Conventional Surgery
Description: Undergo resection of tumor
Study NCT03053960 — intervention group
Intervention type: PROCEDURE
Intervention: Histopathologic Examination
Description: Correlative studies
Study NCT02279537 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Administration by intravitreal injection
Study NCT02864498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS107
Study NCT02864498 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04309539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: A linear probe will be placed in the sagittal plane to the inguinal ligament to obtain an image of bow-tie sign formed by the muscle fascias, a spinal needle will be inserted 1 cm cephalad Using an in-plane approach, the fascia iliaca is penetrated, 30 mL of bupivacaine 0.25% before spinal anesthesia.
Study NCT01069094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucron Depot
Description: 3.75 mg IM monthly
Study NCT04309539 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined LFCN block with PENG block
Description: With the patient supine, the linear probe is placed parallel to the inguinal ligament. LFCN appear as a hypoechoic oval structure between the tensor fascia lata and Sartorius muscles. The needle is inserted in plane. 5 mL of LA is injected. The PENG block will be performed in the supine position. A curvilinear probe will be placed transversely over the anterior inferior iliac spine and then rotated counterclockwise 45 degrees. the ilio pubic eminence, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle will be observed. A spinal needle will be inserted in plane to the plane between the psoas tendon and the pubic ramus. 25 mL of bupivacaine 0.25% will be injected
Study NCT01192516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Activity Pacing
Description: Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
Study NCT01192516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Activity Pacing
Description: Therapeutic intervention using generalized pacing instruction to manage symptoms
Study NCT04189081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry mouth rinse
Description: relieves dry mouth symptoms by physically coating oral mucosal surfaces.
Study NCT04189081 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dry mouth rinse
Description: relieves dry mouth symptoms by physically coating oral mucosal surfaces.
Study NCT04189081 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water Control
Description: negative control
Study NCT02244606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCY-078
Study NCT02244606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Study NCT01069094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as a once daily oral dose for 90 days.
Study NCT02244606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Study NCT04047745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: interscalene nerve block administered before surgery using 133 mg liposomal bupivacaine with 10mL 0.5% ropivacaine
Study NCT04047745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: interscale nerve block administered before surgery using 30mL 0.5% ropivacaine
Study NCT03293589 — intervention group
Intervention type: PROCEDURE
Intervention: open revascularization
Description: surgical revascularization (i.e. Bypass surgery)
Study NCT03293589 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular revascularization
Description: endovascular revascularization (stent, ballon angioplasty)
Study NCT04191720 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted blanket
Description: Patients that were randomly assigned to the intervention group received a weighted blanket to use at their will to reduce anxiety
Study NCT02824952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagrisso
Description: taking orally everyday for 6 or 12 weeks.
Study NCT02248103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Periosteal pedicle graft
Description: Autogenous pedicle graft harvested from the periosteum
Study NCT02248103 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bioresorbable collagen membrane
Description: Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
Study NCT01292434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lunch is in the Bag behavioral intervention
Description: Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
Study NCT03312270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodality information comprehension
Description: Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
Study NCT03493594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Description: online platform support, workshop, seminar and cooking demo etc
Study NCT03612505 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mother groups using principles of UNICEF/World Health Organization's Care for Child Development
Description: The intervention is expected to occur every two weeks for a total of ten sessions. On the study day, the child- caregiver dyads randomised to intervention group will be shown to the study room. Each intervention session will be estimated to last 90 minutes allocated as follows: 6~* Introduction (10 minutes)~* Lesson on \*Early Childhood Development\* topic (20 minutes)~* Discussions on strengthens in caregiving around this topic and areas for improvement (30 minutes)~* Observe caretakers one-on-one in play role with the child (25 minutes)~* Wrap up/Re-cap (5 minutes) Early Childhood development topics that will be covered include per session are: i) Importance of early childhood development ii) Showing love and building trust iii) Awareness of child's well-being iv) Consistency and daily routines v) Discipline and correction vi) consistency and daily routines vii) Nutrition and cleanliness Viii) Importance of play iX) Dealing with life stresses X) Planning for the future
Study NCT02713347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT Intervention
Description: The intervention includes 3 components:~1. nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.~2. social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.~3. collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone.
Study NCT02170597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1048 MS HPMC capsule
Study NCT02170597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBR 1048 MS gelatine capsule
Study NCT03392701 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS infusion
Description: infusion of LPS 2 ng/kg over 5 minutes
Study NCT03392701 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LPS infusion
Description: infusion of LPS 2 ng/kg over 5 minutes
Study NCT04004715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Amino Acid Enriched Whey Protein
Description: protein powder formulation that includes whey and free-form essential amino acids
Study NCT04004715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey Protein
Description: commercially available whey protein isolate
Study NCT04004715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Military Ration Entree
Description: chili and beans entree; current meal component of the meals ready to eat rations
Study NCT00965042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Description: ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
Study NCT01819194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Study NCT01782885 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of PRP
Description: Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
Study NCT01782885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
Study NCT03447067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computer guided surgical
Description: has three cutting guided plane for identify the position of place of the third molar, it have beveled cut for stability after remove the teeth and placing the bony window
Study NCT02765295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)
Description: The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
Study NCT02765295 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Medical molecular mesh oxygen generator
Description: medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.~This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation.
Study NCT03753529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep friction massage
Description: Submitted to three session weekly 30-minute sessions of therapy will performed by the administration of sliding and kneading maneuvers of the masseter and temporalis muscles, bilaterally,lateral pterygoid and digastric over four consecutive weeks (total:12 sessions) Sliding consisted of a unidirectional movement in which part of the therapist's hand (mainly the fingertips) will used, moving from the proximal to the distal portion of the face with constant, progressive pressure compatible with the status of each tissue. The degree of pressure varied depending on the level of pain, sensitivity and tension in each individual. Kneading consisted of a gripping maneuver of a muscle group or portion of a muscle.Then follow-up with a passive stretch to the muscle. This will repeated for three to five times for three sessions per week for 4 weeks.